Related Experiment Video
Updated: Aug 4, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
Scurvy-induced pulmonary arterial hypertension
Jehad Azar1, Mohammed Ayyad2, Yasmin Jaber3
1Pulmonary and Critical Care Department, Cleveland Clinic Foundation, Cleveland, Ohio, USA jehad.azar@gmail.com.
Vitamin C deficiency is linked to pulmonary arterial hypertension (PAH). Supplementation with vitamin C is the definitive treatment for scurvy-induced PAH, addressing low nitric oxide and abnormal transcription factor activation.
Area of Science:
- Cardiovascular Medicine
- Nutritional Science
- Pulmonary Medicine
Background:
- Pulmonary arterial hypertension (PAH) is a severe, progressive disease affecting the pulmonary vasculature.
- PAH involves complex clinical conditions impacting multiple organ systems.
- Existing literature suggests a correlation between vitamin C deficiency and PAH development.
Observation:
- Patients with ascorbic acid deficiency exhibit low endothelial nitric oxide levels.
- Hypoxia-inducible transcription factors are inappropriately activated in vitamin C deficiency.
- These factors contribute to pulmonary vasculopathy and vasoconstriction.
Findings:
- Ascorbic acid deficiency can lead to scurvy-induced PAH.
- Pathogenesis involves reduced nitric oxide and aberrant transcription factor activity.
- Vitamin C supplementation is the established treatment for this condition.
Implications:
- Understanding the role of vitamin C in PAH pathogenesis is crucial.
- Vitamin C supplementation offers a definitive treatment strategy.
- Further research may elucidate novel therapeutic targets for PAH.
More Related Videos
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Pulmonary Embolism I: Introduction
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Rheumatic Heart Disease I: Introduction